{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:48:19Z","timestamp":1776912499052,"version":"3.51.2"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Single-center retrospective case series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>Adult patients admitted to any ICU who received midodrine for hypotension were eligible.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65\u201368; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01). Asymptomatic bradycardia (heart rate &lt; 50 beats\/min) was the most common side effect (<jats:italic toggle=\"yes\">n<\/jats:italic> = 172 patients, median 39 beats\/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000003121","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T14:24:57Z","timestamp":1522765497000},"page":"e628-e633","source":"Crossref","is-referenced-by-count":43,"title":["Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series"],"prefix":"10.1097","volume":"46","author":[{"given":"Mahrukh S.","family":"Rizvi","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vrinda","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faria","family":"Nasim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Kashyap","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Andrijasevic","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ognjen","family":"Gajic","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230728","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.hrtlng.2010.04.007","article-title":"Characteristics of patients receiving vasopressors.","volume":"40","author":"Benbenishty","year":"2011","journal-title":"Heart Lung"},{"key":"R2-20230728","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/cc8853","article-title":"Prevention of central venous catheter-related infection in the intensive care unit.","volume":"14","author":"Frasca","year":"2010","journal-title":"Crit Care"},{"key":"R3-20230728","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/ndt\/gfh420","article-title":"Midodrine appears to be safe and effective for dialysis-induced hypotension: A systematic review.","volume":"19","author":"Prakash","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20230728","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1478-3231.2008.01734.x","article-title":"Prevention of paracentesis-induced circulatory dysfunction: Midodrine vs albumin. A randomized pilot study.","volume":"28","author":"Appenrodt","year":"2008","journal-title":"Liver Int"},{"key":"R5-20230728","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.0000000000000815","article-title":"Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review.","volume":"83","author":"Izcovich","year":"2014","journal-title":"Neurology"},{"key":"R6-20230728","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2165\/00003495-198938050-00004","article-title":"Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.","volume":"38","author":"McTavish","year":"1989","journal-title":"Drugs"},{"key":"R7-20230728","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"R8-20230728","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1751-7133.2008.00042.x","article-title":"The use of midodrine in patients with advanced heart failure.","volume":"15","author":"Zakir","year":"2009","journal-title":"Congest Heart Fail"},{"key":"R9-20230728","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/HYPERTENSIONAHA.114.04225","article-title":"Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.","volume":"64","author":"Ramirez","year":"2014","journal-title":"Hypertension"},{"key":"R10-20230728","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10286-016-0363-9","article-title":"Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: A phase 4, double-blind, placebo-controlled, randomized, tilt-table study.","volume":"26","author":"Smith","year":"2016","journal-title":"Clin Auton Res"},{"key":"R11-20230728","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/107424840501000109","article-title":"Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy.","volume":"10","author":"Sharma","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R12-20230728","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1074248408317709","article-title":"Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting.","volume":"13","author":"Sharma","year":"2008","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R13-20230728","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jcrc.2013.05.021","article-title":"Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.","volume":"28","author":"Levine","year":"2013","journal-title":"J Crit Care"},{"key":"R14-20230728","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-20230728","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1345\/aph.1P468","article-title":"Impact of early postoperative hydrocortisone administration in cardiac surgical patients after cardiopulmonary bypass.","volume":"45","author":"Ensor","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R16-20230728","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chest.2016.02.657","article-title":"Feasibility, utility, and safety of midodrine during recovery phase from septic shock.","volume":"149","author":"Whitson","year":"2016","journal-title":"Chest"},{"key":"R17-20230728","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock.","volume":"358","author":"Sprung","year":"2008","journal-title":"N Engl J Med"},{"key":"R18-20230728","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.chest.2016.11.036","article-title":"Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study.","volume":"151","author":"Marik","year":"2017","journal-title":"Chest"},{"key":"R19-20230728","first-page":"211","article-title":"[Infectious toxic hypotension\u2013effect and dosage of midodrine (author\u2019s transl)].","volume":"14","author":"Weippl","year":"1979","journal-title":"Padiatr Padol"},{"key":"R20-20230728","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jcpt.12375","article-title":"Midodrine for the weaning of vasopressor infusions.","volume":"41","author":"Poveromo","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"R21-20230728","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.chest.2016.03.054","article-title":"Considerations on midodrine use in resolving septic shock.","volume":"149","author":"Hammond","year":"2016","journal-title":"Chest"},{"key":"R22-20230728","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12871-017-0339-x","article-title":"Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: A multicenter, randomized, placebo controlled trial (the MIDAS trial).","volume":"17","author":"Anstey","year":"2017","journal-title":"BMC Anesthesiol"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003246-201807000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T10:15:14Z","timestamp":1690539314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003246-201807000-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000003121","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}